Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept

J Rheumatol. 2008 Dec;35(12):2313-5. doi: 10.3899/jrheum.080356. Epub 2008 Oct 1.


Objective: Dickkopf-1 (Dkk-1) regulates bone remodeling in animal models of inflammatory arthritis, but its role in patients with rheumatoid arthritis (RA) remains unclear.

Methods: Baseline circulating Dkk-1 was measured in 113 patients with RA (< 3 yrs) who received etanercept (10 or 25 mg twice/week, n = 63) or methotrexate alone (n = 40) for 1 year. Progression was assessed by changes in radiological Sharp score.

Results: Increased Dkk-1 was associated with a higher risk of progression of bone erosion, independently of age, sex, baseline radiological damage, C-reactive protein, and disease activity in patients treated with etanercept.

Conclusion: Dkk-1 may be an important mediator of bone erosion in patients with RA.

MeSH terms

  • Adult
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / blood*
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / pathology
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Intercellular Signaling Peptides and Proteins / blood*
  • Male
  • Methotrexate / therapeutic use
  • Middle Aged
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Risk
  • Severity of Illness Index


  • Antirheumatic Agents
  • DKK1 protein, human
  • Immunoglobulin G
  • Immunologic Factors
  • Intercellular Signaling Peptides and Proteins
  • Receptors, Tumor Necrosis Factor
  • Etanercept
  • Methotrexate